Scientists will publish a formal research review in a major journal (impact factor above 5 — meaning it's in the top tier of prestigious publications) that examines all the MDMA-assisted therapy trials and measures exactly how badly the blinding failed. Blinding failure means patients could tell whether they got real MDMA or placebo, which inflates how good the drug looks. This study will quantify the problem across multiple trials and show it's systematic, not a one-off mistake.
The blinding integrity problem is now the central scientific controversy in the field, with multiple groups independently collecting data. A meta-analysis is the natural methodological culmination and would be highly damaging to approval narratives. Specific falsifiability criteria: peer-reviewed, impact factor >5, focused on blinding failure quantification, published before March 31 2027.